GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » EV-to-Revenue

Regen BioPharma (Regen BioPharma) EV-to-Revenue : 16.66 (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Regen BioPharma's enterprise value is $3.93 Mil. Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.24 Mil. Therefore, Regen BioPharma's EV-to-Revenue for today is 16.66.

The historical rank and industry rank for Regen BioPharma's EV-to-Revenue or its related term are showing as below:

RGBP' s EV-to-Revenue Range Over the Past 10 Years
Min: 10.88   Med: 48.23   Max: 1806.45
Current: 16.66

During the past 11 years, the highest EV-to-Revenue of Regen BioPharma was 1806.45. The lowest was 10.88. And the median was 48.23.

RGBP's EV-to-Revenue is ranked worse than
61.84% of 1043 companies
in the Biotechnology industry
Industry Median: 8.21 vs RGBP: 16.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Regen BioPharma's stock price is $0.685. Regen BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.06. Therefore, Regen BioPharma's PS Ratio for today is 10.87.


Regen BioPharma EV-to-Revenue Historical Data

The historical data trend for Regen BioPharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma EV-to-Revenue Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.80 28.45 791.18 143.97 29.39

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.94 29.81 29.39 17.60 15.69

Competitive Comparison of Regen BioPharma's EV-to-Revenue

For the Biotechnology subindustry, Regen BioPharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's EV-to-Revenue falls into.



Regen BioPharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Regen BioPharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.932/0.236
=16.66

Regen BioPharma's current Enterprise Value is $3.93 Mil.
Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma  (OTCPK:RGBP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Regen BioPharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.685/0.063
=10.87

Regen BioPharma's share price for today is $0.685.
Regen BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.